Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2024-04-25 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物科技（上海）股份有限公司章程（2024年4月修订）
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 益方生物科技（上海）股份有限公司 (InventisBio Co., Limited). It includes chapters on general provisions, business scope, share issuance, share transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, audit, notices and announcements, mergers, amendments to the charter, and other governance matters. The content is focused on the company's internal governance rules, shareholder rights and obligations, board structure, meeting procedures, and related corporate governance topics. There is no indication of financial statements, audit reports, earnings data, or regulatory filings. The document is not a report of financial results or an announcement but a governance document outlining the company's internal rules and structure. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2024-04-25 Chinese
益方生物董事会关于独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors. It references regulatory rules about independent directors and confirms their independence status. The document is short (477 characters) and focuses on governance and compliance related to board members' independence. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. It is not an announcement of a report, nor a full annual or interim report, nor a certification or voting result. Therefore, the best classification is CGR with high confidence.
2024-04-25 Chinese
益方生物科技（上海）股份有限公司2023年年度报告
Annual Report Classification · 100% confidence The document is titled '2023 年年度报告' which translates to '2023 Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, risk factors, and extensive information on research and development activities. The document includes audited financial statements, signed audit reports, and comprehensive disclosures typical of a full annual report. The length of the document (15,000 characters) and the presence of detailed financial and operational data confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-25 Chinese
益方生物独立董事2023年度述职报告（严嘉）
Board/Management Information Classification · 95% confidence The document is an Independent Director's 2023 Annual Work Report for Yifang Biotechnology (Shanghai) Co., Ltd. It details the independent director's background, attendance at board and committee meetings, communication with auditors, review of financial reports, and governance activities during the year 2023. It includes no financial statements or quarterly/annual financial data but focuses on governance, oversight, and director duties. This type of document is a management or board-related report describing director activities and governance oversight rather than a financial report or announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is 3840 characters, which is relatively short but contains substantive content about board activities, not just an announcement or certification. Hence, it is not RNS or RPA. Confidence is high due to clear content and purpose.
2024-04-25 Chinese
益方生物2023年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度募集资金存放与实际使用情况的专项报告" which translates to "2023 Annual Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised, their deposit, usage, management, and changes in investment projects related to the raised funds. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes detailed financial figures and tables about the use of the raised capital. The document is a comprehensive report on the management and use of capital raised by the company, not merely an announcement or a brief summary. It is not an earnings release, annual report, or interim report, but a specialized report focused on capital raising and usage. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length (8534 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the correct classification is CAP with high confidence.
2024-04-25 Chinese
益方生物董事会审计委员会对会计师事务所履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm (Dahua CPA Firm) for the 2023 annual audit. It details the audit firm's qualifications, the audit process, communication with management, and the committee's evaluation of the audit work. It references the 2023 annual financial report and audit report but does not contain the full annual report or financial statements itself. The document is focused on the audit committee's oversight and the audit firm's performance, which aligns with an Audit Report / Information filing rather than the full Annual Report (10-K). The document length is 2099 characters, which is relatively short and consistent with a standalone audit report or audit committee report rather than a full annual report. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2023
2024-04-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.